Hemoglobin A1c predicts heart failure hospitalization independent of baseline cardiac function or B-type natriuretic peptide level

Diabetes Research and Clinical Practice

Volumn 104, Issue 2, 2014, Pages 257-265

  Kishimoto, Ichiro ^a   Makino, Hisashi ^a   Ohata, Yoko ^a   Tamanaha, Tamiko ^a   Tochiya, Mayu ^a   Kada, Akiko ^a   Ishihara, Masaharu ^a   Anzai, Toshihisa ^a   Shimizu, Wataru ^a   Yasuda, Satoshi ^a   Ogawa, Hisao ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Glycated hemoglobin; Heart failure; Type 2 diabetes

Indexed keywords

GLYCATED HEMOGLOBIN; HEART FAILURE; TYPE 2 DIABETES;

AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; JAPAN; MALE; NATRIURETIC PEPTIDE, BRAIN; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION;

EID: 84898833180     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.02.009     Document Type: Article

References (32)

1. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. Circulation 2005, 112:e154-e235.
2. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884.
3. Krumholz H.M., Chen Y.T., Wang Y., Vaccarino V., Radford M.J., Horwitz R.I. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000, 139:72-77.
4. Shindler D.M., Kostis J.B., Yusuf S., Quinones M.A., Pitt B., Stewart D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996, 77:1017-1020.
5. Iribarren C., Karter A.J., Go A.S., Ferrara A., Liu J.Y., Sidney S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103:2668-2673.
6. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
7. 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2008, 51:2197-2204.
8. Zhang Y., Hu G., Yuan Z., Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 2012, 7:e42551.
9. Bell D.S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003, 26:2433-2441.
10. Annonu A.K., Fattah A.A., Mokhtar M.S., Ghareeb S., Elhendy A. Left ventricular systolic and diastolic functional abnormalities in asymptomatic patients with non-insulin-dependent diabetes mellitus. J Am Soc Echocardiogr 2001, 14:885-891.
11. Epshteyn V., Morrison K., Krishnaswamy P., Kazanegra R., Clopton P., Mudaliar S., et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003, 26:2081-2087.
12. Zabalgoitia M., Ismaeil M., Anderson L., Maklady F. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well controlled type 2 diabetes mellitus. Am J Cardiol 2001, 87:320-323.
13. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
14. Kishimoto I., Tokudome T., Nakao K., Kangawa K. Natriuretic peptide system: an overview of studies using genetically engineered animal models. FEBS J 2011, 278:1830-1841.
15. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87:1402-1412.
16. Yoshimura M., Yasue H., Okumura K., Ogawa H., Jougasaki M., Mukoyama M., et al. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with CHF. Circulation 1993, 87:464-469.
17. Maeda K., Tsutamoto T., Wada A., Hisanaga T., Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high LV end-diastolic pressure in patients with symptomatic LV dysfunction. Am Heart J 1998, 135:825-832.
18. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., et al. Biochemical detection of LV systolic dysfunction. Lancet 1998, 351:9-13.
19. Rehman S.U., Januzzi J.L. Natriuretic peptide testing in primary care. Curr Cardiol 2008, 4:300-308.
20. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021.
21. Marwick T.H. Diabetic heart disease. Heart 2006, 92:296-300.
22. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
23. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
24. Currie C.J., Peters J.R., Tynan A., Evans M., Heine R.J., Bracco O.L., et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
25. Aguilar D., Bozkurt B., Ramasubbu K., Deswal A. Relationship of hemoglobin A1c and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009, 54:422-428.
26. Nichols G.A., Joshua-Gotlib S., Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol 2013, 62:121-127.
27. Lind M., Bounias I., Olsson M., Gudbjörnsdottir S., Svensson A.M., Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011, 378:140-146.
28. Lind M., Olsson M., Rosengren A., Svensson A.-M., Bounias I., Gudbjörnsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia 2012, 55:2946-2953.
29. Zhao W., Katzmarzyk P.T., Horswell R., Wang Y., Johnson J., Hu G. HbA1c and heart failure risk among diabetic patients. J Clin Endocrinol Metab 2013, (December). [Epub ahead of print].
30. Weinrauch L.A., Lewis E.F. Aiming for the best control of glycemia in patients with heart failure and type 2 diabetes: the sweet spot. J Am Coll Cardiol 2009, 54:429-431.
31. Ismail-Beigi F., Moghissi E., Tiktin M., Hirsch I.B., Inzucchi S.E., Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011, 154:554-559.
32. American Diabetes Association Standards of Medical Care in Diabetes-2013 Diabetes Care 2013, 36(Suppl. 1):S11-S66.